An observational study in Atrial Fibrillation (AF) and Major Gastrointestinal Bleeding (MGIB), sponsored by Società Italiana di Medicina Interna. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Società Italiana di Medicina Interna · Observational
Among 252 studies in Atrial Fibrillation with a site in Italy — 44 open to participants now, 64 under way, 2 of them phase 3. Atrial Fibrillation · Italy.
Among the 252 studies in Atrial Fibrillation with a site in Italy, this one is the 37th largest by planned enrollment of the 95 observational ones, is one of 14 that started in 2024, is one of 95 observational ones, reaches primary completion later than 24 of the 63 other live ones, and was the 252nd registered.
4,009 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
This study's planned enrollment of 650 is above the median of 300 across 1,400 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →44 of the 252 studies in Atrial Fibrillation with a site in Italy are open now, in 12 countries. Each count lists the studies.
Of the 612 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →252 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 14 started in 2024.
Median enrollment 321 across the 156 interventional studies, 411 across the 95 observational. Of the 154 that completed or were terminated, 72 (47%) have results posted.
129 of 252 have an industry lead sponsor. The 10 most frequent:
Società Italiana di Medicina Interna is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Società Italiana di Medicina Interna has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
22 of the studies in Atrial Fibrillation with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07901699Società Italiana di Medicina InternaResumption of Anticoagulation After Major Gastrointestinal Bleeding in Patients With Atrial Fibrillation | 2026-11 |
| NCT05005949Medtronic Cardiac Ablation SolutionsSTOP Persistent AF PAS | 2026-12 |
| NCT07429214Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF | 2026-12-30 |
| NCT07428564Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE PRO Software in Participants With PsAF | 2026-12-30 |
Among the 252 studies in Atrial Fibrillation with a site in Italy, from their registry updates:
Prospective multicenter observational study on resumption of anticoagulant therapy after major gastrointestinal bleeding in patients with atrial fibrillation
Prospective multicenter observational study with central blinded and independent adjudication of primary outcome on resumption of anticoagulant therapy after major gastrointestinal bleeding in patients with atrial fibrillation
The criteria were revised on the registry on Nov 2, 2026. See what changed
Consecutive patients fulfilling inclusion criteria and with no exclusion criterion
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Major gastrointestinal bleeding as assessed by the central independent adjudication committee
Recurrence of Major GIB at 90 days as assessed by the central independent adjudication committee
Time frame: 90 days
Plan to share: Yes — based on a specific request
Supporting information: Study protocol
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Nov 2026, 34 months after the start.
Of 550 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 34 months is below that.
Counting every sponsor, half of 698 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Società Italiana di Medicina Interna